ImmunoCellular Therapeutics, Ltd. (OTC BB: IMUC)

ImmunoCellular Therapeutics, Ltd. (OTC BB: IMUC), a clinical-stage company, is focused on developing new therapeutics to fight cancer using the human body’s immune system. Their product pipeline consists of cellular immunotherapies that target brain cancer, and monoclonal antibodies designed to diagnose and treat various cancers. The company’s lead product candidate is currently in a Phase I clinical trial to treat glioblastoma multiforme, the most common type of brain tumor. For further information, visit the Company’s web site at www.imuc.com.